Accessibility Menu
Oncology Pharma logo

Oncology Pharma(OTC) ONPH

Market Cap$1.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-100%
5 Year-100%
1 Year+25,400%
1 Month-15%
$0.05
+0.00%
+0.00Today
Oncology Pharma last closing stock price
MetricPriceDate
Last closeUSD 0.052026-08-19
Oncology Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-25.55%USD 0.072026-08-12
1 month-15.07%USD 0.062026-07-20
3 month-36.25%USD 0.082026-05-21
Year to date+1,175%USD 0.002025-12-31
1 year+25,400%USD 0.002025-08-19
3 year-32%USD 0.082023-08-18
5 year-99.67%USD 15.422021-08-20
Since inception-100%USD 1,000,000,000.001992-05-13

Oncology Pharma Financials at a Glance

Market Cap

$1.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$5.60M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-1193.96 (Low)

Price

$0.05

Volume

5,888

Open

$0.05

Previous Close

$0.05

Daily Range

$0.05 - $0.05

52-Week Range

$0.05 - $0.36

Estimated Earnings Date

Feb 15, 2004

ONPH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Oncology Pharma

Oncology Pharma Inc. is a biotechnology company focused on developing, manufacturing, and commercializing therapeutic agents for oncology. The firm is also exploring treatment possibilities for COVID-19 through a collaboration with Kalos Therapeutics Inc.

Products and Services
  • Development of oncology therapeutic agents
  • Collaborative research on COVID-19 treatments
  • Manufacturing capabilities for pharmaceutical products
Growth Outlook
  • Potential expansion in oncology market driven by increasing cancer cases
  • Collaborative agreement with Kalos Therapeutics may enhance product pipeline
  • Focus on innovative therapies aligns with industry trends
Financial Highlights
  • Recent quarterly net income of -$820, indicating ongoing investment in R&D
  • Trailing twelve months (TTM) revenue remains at $0, reflecting early-stage development
  • Market capitalization of approximately $1.88 million, suggesting growth potential
Oncology Pharma Inc. operates in a highly competitive biotechnology sector, with a focus on oncology and emerging health threats like COVID-19. The company's strategic partnerships and innovative approach position it well for future growth. Despite current financial challenges, the potential for significant advancements in cancer treatment and other therapeutic areas remains a key driver for investor interest. The firm’s commitment to research and development, coupled with its collaborative efforts, may lead to breakthroughs that could enhance its market position and financial performance in the long term.
AI Generated • Aug 20, 2026

Industry

Biotechnology

Sector

Health Care

CEO

George Malesek

Website

www.SourcingLink.net

Headquarters

San Francisco, CA 94104, US

ONPH Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-1.08%

Return on Capital

-0.30%

Return on Assets

-0.27%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

27.39M

Volume

5.89K

Avg. Volume

24.18K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$100.94K

EBITDA

-$100.94K

Operating Cash Flow

-$69.37K

Capital Expenditure

$0.00

Free Cash Flow

-$69.37K

Cash & ST Invst.

$398.00

Total Debt

$777.62K

Oncology Pharma Performance Analysis

Oncology Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-03-31USD 0N/A
20252025-12-31USD 0N/A
Oncology Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-06-30N/A
Q22022-09-30N/A
Q32022-12-31N/A
Q32025-12-31N/A
Oncology Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-03-31USD -3.42N/A
20252025-12-31USD -0.00-100.0%
Oncology Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-06-30N/A
Q22022-09-30-21328.6%
Q32022-12-3195.6%
Q32025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.40M

N/A

Employees

1

N/A

Net Income

-$820.00

+99.0%

EBITDA

-$820.00

+99.0%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

$398.00

-80.1%

Total Debt

$777.62K

+362.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$777.62K

+362.9%

Return on Assets

-0.27%

N/A

Return on Invested Capital

-0.47%

N/A

Free Cash Flow

-$1.98K

-98.4%

Operating Cash Flow

-$1.98K

-98.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AMPEAmpio Pharmaceuticals, Inc.
$0.18+0.00%
WUHNWuhan General Group (China), Inc.
$0.00+0.00%
BTTXBetter Therapeutics, Inc.
$0.00+0.00%
PANCPanacos Pharmaceuticals, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.81+0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.72-0.05%
SPCXSpace Exploration Technologies
$132.06-0.05%
IBITiShares Bitcoin Trust
$41.08+0.06%

Questions About ONPH

What is the current price of Oncology Pharma?

Oncology Pharma is trading at $0.05 per share.

What is the 52-week range for Oncology Pharma?

Over the past 52 weeks, Oncology Pharma has traded between $0.05 and $0.36.

How much debt does Oncology Pharma have?

As of the most recent reporting period, Oncology Pharma reported total debt of $0.00.

How much cash does Oncology Pharma have on hand?

Oncology Pharma reported $42.01K in cash and cash equivalents in its most recent financial results.

What is Oncology Pharma’s dividend yield?

Oncology Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services